2010 - TTS International Congress


Clinical Immunosuppression Kidney late

19.22 - The effect of change or modulation of maintain immunosuppressive regimen on long-term transplant result

Presenter: Kyu Ha, Huh, Seoul, Korea
Authors: Huh K., Kim Y., Lee J., Kim M., Kim S., Park K.


THE EFFECT OF CHANGE OR MODULATION OF MAINTAIN IMMUNOSUPPRESSIVE REGIMEN ON LONG-TERM TRANSPLANT RESULT

CLINICAL IMMUNOSUPPRESSION - KIDNEY LATE

K.H. Huh1, Y.S. Kim2, J.J. Lee1, M.S. Kim2, S.I. Kim2, K. Park3
1Surgery, Yonsei university college of medicine, Seoul/KOREA, 2, Yonsei university college of medicine, Seoul/KOREA, 3, CHA Bundang Medical Center, Seongnam/KOREA

Body: Introduction: Type of maintenance immunosuppressive regimen (ISR) is a major prognostic factor that determines graft survival. Therefore, a change or modulation of the ISR may be a potential determinant that affect the transplant results. This study evaluates the effects of change or modulation of ISR on long-term transplant results. Methods: A total of 1,164 patients that underwent kidney transplantation from January, 1997 to December, 2008 in Yonsei University Health System were enrolled in this study. The change mode of immunosuppressant, the reason for change, and the transplant results were retrospectively collected. Results: Among 1,164 kidney transplant recipients, 201 recipients (17.3%) were started under the double regimen (DR) (calcineurin inhibitor (CNI) and steroid) and 963 recipients (82.7%) were under triple regimen (TR) (CNI+steroid+antimetabolite). Seventy-seven recipient (38.3%) with DR and 271 recipients (28.1%) with TR were changed ISR during post-transplant period. Among the recipient with DR, the most frequent reason for regimen change was acute rejection in early post-transplant period and chronic allograft dysfunction in late period. Conversion to TR (69/201, 34.3%) was predominant change mode of recipient with initial DR. Unlike recipient with DR, major causes of regimen change in recipients with TR were complications related with over-immunosuppression and drug toxicity regardless of post-transplant period. Conversion to DR and change of antimetabolite were performed in 127 recipients (127/ 963, 12.6%) and 98 recipient (98/963, 10.2%) respectively. The change group of initial DR showed statistically superior graft survival rate (GSR) (p=0.032) compared with maintain group of initial DR. On the other hand, the change group of initial TR showed inferior GSR (p<0.001). [Figure] Conclusion: The cause and mode of regimen change was clearly different by type of initial regimen. And effect of regimen change on transplant result was also different. The type of regimen after post-transplant change or modulation affects the long-term transplant result. The triple maintain regimen with antimetabolite showed a superior GSR.

Disclosure: All authors have declared no conflicts of interest.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi